EPS for Albany Molecular Research, Inc. (AMRI) Expected At $0.23, Mfri (MFRI)’s Sentiment Is 1

July 17, 2017 - By Hazel Jackson

Analysts expect Albany Molecular Research, Inc. (NASDAQ:AMRI) to report $0.23 EPS on August, 3.They anticipate $0.09 EPS change or 28.13% from last quarter’s $0.32 EPS. AMRI’s profit would be $9.84M giving it 23.55 P/E if the $0.23 EPS is correct. After having $0.13 EPS previously, Albany Molecular Research, Inc.’s analysts see 76.92% EPS growth. About 649,111 shares traded. Albany Molecular Research, Inc. (NASDAQ:AMRI) has risen 27.56% since July 17, 2016 and is uptrending. It has outperformed by 10.86% the S&P500.

Perma-Pipe International Holdings, Inc., formerly MFRI, Inc., is engaged in the manufacture and sale of piping systems. The company has market cap of $59.83 million. The Firm is engaged in offering pre-insulated piping and leak detection systems for gas and oil gathering, district heating and cooling, and other applications. It currently has negative earnings. It operates through Piping Systems segment.

It is down 0.00% since July 17, 2016 and is . It has underperformed by 16.70% the S&P500.

Cannell Capital Llc holds 0.86% of its portfolio in Perma-Pipe International Holdings Inc for 333,354 shares. First Wilshire Securities Management Inc owns 228,891 shares or 0.53% of their US portfolio. Moreover, Morgan Dempsey Capital Management Llc has 0.32% invested in the company for 136,440 shares. The Massachusetts-based Crow Point Partners Llc has invested 0.19% in the stock. Perritt Capital Management Inc, a Illinois-based fund reported 54,507 shares.

Among 5 analysts covering Albany Molecular (NASDAQ:AMRI), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. Albany Molecular had 5 analyst reports since October 26, 2015 according to SRatingsIntel. The stock of Albany Molecular Research, Inc. (NASDAQ:AMRI) has “Hold” rating given on Thursday, June 8 by J.P. Morgan. The firm earned “Overweight” rating on Monday, October 26 by First Analysis. The stock has “Hold” rating by William Blair on Tuesday, June 6. As per Thursday, May 11, the company rating was downgraded by Morgan Stanley. The rating was downgraded by JP Morgan on Thursday, June 8 to “Neutral”.

Investors sentiment increased to 1.2 in Q4 2016. Its up 0.25, from 0.95 in 2016Q3. It increased, as 14 investors sold Albany Molecular Research, Inc. shares while 36 reduced holdings. 15 funds opened positions while 45 raised stakes. 30.62 million shares or 2.12% more from 29.98 million shares in 2016Q3 were reported. 116,078 are held by Deutsche Bankshares Ag. Mutual Of America Capital Mgmt Lc invested 0.05% of its portfolio in Albany Molecular Research, Inc. (NASDAQ:AMRI). Loomis Sayles And Co L P accumulated 654,848 shares. Proshare Advsrs Limited Liability Corp accumulated 33,005 shares. Fisher Asset Mgmt Lc reported 0% of its portfolio in Albany Molecular Research, Inc. (NASDAQ:AMRI). Morgan Stanley reported 616,598 shares or 0% of all its holdings. State Of Alaska Department Of Revenue holds 2,410 shares. Aperio Grp Ltd Limited Liability Company reported 0% in Albany Molecular Research, Inc. (NASDAQ:AMRI). Palisade Cap Mngmt Nj owns 655,312 shares. Invesco stated it has 0% of its portfolio in Albany Molecular Research, Inc. (NASDAQ:AMRI). Obermeyer Wood Investment Counsel Lllp reported 3.15% in Albany Molecular Research, Inc. (NASDAQ:AMRI). California-based California Employees Retirement System has invested 0% in Albany Molecular Research, Inc. (NASDAQ:AMRI). California State Teachers Retirement Sys stated it has 53,596 shares or 0% of all its holdings. Arizona State Retirement Sys reported 0% in Albany Molecular Research, Inc. (NASDAQ:AMRI). Panagora Asset Mngmt has 0% invested in Albany Molecular Research, Inc. (NASDAQ:AMRI) for 12,315 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.